3648 results for «2520»
3648 results
Patient selection for tricuspid TEER in 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...
Procedural optimisation for enhanced acute and long-term outcomes
14 Feb 2026 – From PCR Tokyo Valves 2026
This session emphasizes procedural optimization in TAVI to enhance both acute and long-term outcomes. It highlights critical factors such as valve sizing, expansion, implantation depth, and commissural alignment. Practical techniques for pre- and post-dilatation alongside commissural alignment are demonstrated through real cath lab cases, underscoring their...
TAVI: new evidence and clinical trials
14 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest evidence from head-to-head clinical trials comparing contemporary TAVI devices, including detailed discussions of the LANDMARK and COMPARE trials. It also highlights ongoing and upcoming clinical trials poised to influence guideline recommendations and expand the therapeutic scope of TAVI, providing crucial insights...
Team approach to structural heart disease: how to handle unexpected situations
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...
From diagnosis to device: decision-making and planning for mitral valve interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a structured approach to mitral TEER, integrating advanced imaging techniques for detailed mitral valve morphology evaluation, procedural planning, and complication prediction. It highlights device selection considerations and emerging technologies to tailor interventions for complex mitral valve disease, supported by multiple case presentations and...
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Healthcare professionals in the structural heart disease treatment
15 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the essential roles and contributions of various healthcare professionals involved in structural heart disease treatment. It offers insights into the unique responsibilities of medical technologists, nurses, and radiological technologists across preoperative, intraoperative, and postoperative stages, fostering collaboration and sharing practical tips to strengthen...
Complications and bailout strategies in transcatheter mitral interventions
15 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses complications arising during transcatheter mitral edge-to-edge repair (TEER), focusing on identification, anticipation, and management strategies. It also highlights the importance of case selection to improve procedural safety, supported by detailed case analyses covering leaflet/device, access/septal, and hemodynamic complications.
Transcatheter electrosurgery and leaflet modification of the aortic valve
15 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...
GulfPCR-GIM 2025 Opening Ceremony
10 Dec 2025 – From GulfPCR-GIM 2025
The GulfPCR-GIM 2025 Opening Ceremony marks the commencement of this prestigious cardiology congress, setting the tone for a comprehensive program dedicated to advancing interventional cardiology practice and research in the Gulf region and beyond.
GulfPCR-GIM 2025 Closing Ceremony
11 Dec 2025 – From GulfPCR-GIM 2025
The GulfPCR-GIM 2025 Closing Ceremony marks the conclusion of an insightful and comprehensive congress, highlighting the latest advances and discussions in interventional cardiology. This session encapsulates the key takeaways and emerging themes that will shape future clinical practice and research in cardiology.
Beyond the trial: how will SELUTION DeNovo redefine our PCI practice?
10 Dec 2025 – From GulfPCR-GIM 2025
This session looks beyond trial data to examine how the SELUTION DeNovo study may reshape PCI practice in real-world settings.
The discussion reviews key clinical results from this large-scale DeNovo PCI trial and explains the technology behind the SELUTION SLR drug-eluting balloon, including its slow-flow drug delivery...
Design that delivers the future of TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
This session presents the future of TAVI valve design, emphasizing supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches tailored for long-term patient management.
Built to last: lifetime management for durability and beyond
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the principles of lifetime management aimed at durability and optimal long-term outcomes in complex valvular heart disease cases. Key topics include the critical importance of initial valve choice, practical tips for optimizing paravalvular leak (PVL) management, and advanced strategies for redo transcatheter aortic...
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...
When mitral disease is not the only problem on mitral TEER patients
22 May 2025 – From EuroPCR 2025
Explore the multifaceted challenges in patients undergoing mitral TEER when additional mitral and tricuspid pathologies coexist. This session reviews data from the EXPANDed studies on tricuspid regurgitation post-mitral TEER, one-year outcomes based on cardiac damage extent, pulmonary hypertension dynamics, and the long-term mortality causes in this...
TAVI coronary access
22 May 2025 – From EuroPCR 2025
Gain expertise in managing coronary access challenges in TAVI patients. This session discusses when and how to treat coronary lesions in TAVI candidates, strategies to facilitate coronary approach post-TAVI, and long-term outcomes with practical tips through illustrative cases including primary PCI after CoreValve implantation and valve-in-valve...
Difficult decision-making in left main revascularisation
22 May 2025 – From EuroPCR 2025
Address difficult clinical decisions in left main coronary artery revascularization through this session featuring complex cases. Topics include prioritization in combined left main, aortic valve disease, and low ejection fraction, management of myocardial infarction with severe mitral regurgitation and cardiogenic shock, and unique cases such as...
When angina cannot be cured with stents: what are the remaining options
22 May 2025 – From EuroPCR 2025
Explore therapeutic options for patients with angina refractory to stenting. This session reviews the efficacy and clinical outcomes of coronary sinus (CS) reducer implantation for microvascular dysfunction, factors influencing procedural success, next-generation CS reducer innovations, and the role of aspirin in angina without obstructive coronary disease.
